Abstract
Very elderly (> 75 years) chronic myeloid leukaemia (CML) patients at diagnosis are sometimes treated with different doses of imatinib (IM) based on concomitant diseases and physicians’ judgement. However, data on long-term follow-up of these patients are still lacking. To investigate treatment response and outcome, we retrospectively revised an Italian database of 263 very elderly CML patients receiving IM from the time of diagnosis. Median age at diagnosis was 78.5 years and 56% of patients had 2 or 3 comorbidities. A complete haematological and cytogenetic response were achieved in 244 (92.8%) and 184 (69.9%) patients, respectively. In 148 cases (56.2%), a major molecular response was observed, which was deep in 63 cases (24%). A blastic phase occurred in 11 patients (4.2%). After a median follow-up of 45.0 months, 93 patients have died (9 from disease progression) and 104 (39.5%) are still in treatment with IM. Incidence of grades 3–4 haematological and non-haematological toxicity was similar to those reported in younger patients. Five-year event-free survival was 54.5% and 45.2% in patients ≤ 80 years and > 80 years, respectively (p = 0.098). Five years OS was 75.7% and 61.6% in patients ≤80 years and > 80 years, respectively (p = 0.003). These findings show that IM plays an important role in frontline treatment of very elderly CML patients without increased toxicity and any effort to treat these patients with standard doses should be made in order to achieve responses as in younger subjects.
Similar content being viewed by others
References
Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, di Raimondo F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, Hehlmann R (2015) The EUTOS population-based registry: incidence and clinical characteristics of 2940 CML patients in 20 European countries. Leukemia 29:1336–1343
Castagnetti F, Di Raimondo F, De Vivo A et al (2017) A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. Am J Hematol 92:82–87
Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukemia (CML). Best Pract Res Clin Haematol 22(3):295–302
Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63(4):789–799
Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon-alpha. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11):850–858
Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, Poerio A, Soverini S, Palandri F, Cambrin GR, Iuliano F, Alimena G, Latagliata R, Testoni N, Pane F, Saglio G, Baccarani M, Martinelli G (2007) Impact of age on the outcome of patients with chronic myelodi leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologca 92:101–105
Latagliata R, Breccia M, Carmosino I, Cannella L, De Cuia R, Diviero D et al (2010) “Real-life” results of front-line treatment with imatinib in older patients (>/= 65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res 34(11):1472–1475
Breccia M, Tiribelli M, Alimena G (2012) Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol 84:93–100
Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118:686–692
Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann VS, Castagnetti F, Hasford J, Hehlmann R, Simonsson B (2016) Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30:48–56
Druker BJ, Gulhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417
Latagliata R, Carmosino I, Vozella F, Volpicelli P, de Angelis F, Loglisci MG, Salaroli A, de Luca ML, Montagna C, Serrao A, Molica M, Diverio D, Nanni M, Mancini M, Breccia M, Alimena G (2017) Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a ‘real-life’ patient population with chronic myeloid leukaemia. Hematol Oncol 35(2):232–236
Hochhaus A, Larson Richard A, Guilot F et al (2017) Long term outcome of Imatinib treatment for chronic myeloid leukemia. N Engl J Med 376:917–927
Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D’Addosio A, Rege-Cambrin G, Luciano L, Alimena G (2013) Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. Drugs Aging 30:629–637
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884
Cross NC, White HE, Muller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172–2175
Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G, on behalf of the Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 117:5591–5599
Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G (2015) Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol 26(1):185–192
Krishna B Ghimire and Binay K. Shah. Chronic myeloid leukemia survival in older population in pre- and post- imatinib era in the United States. Blood 2012; 120:4237 (abstract)
Breccia M, Palandri F, Luciano L, Benevolo G, Bonifacio M, Caocci G, Castagnetti F, Palumbo GA, Iurlo A, Landi F (2018) Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. Ann Hematol 97(5):745–754
Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE (2015) Relative survival in patients with chronic-phase chronic myeloid leukemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186–e193
OECD and the European Observatory on Health Systems and Policies. State of Health in the EU—Italy. Healthcare profile 2017. http://www.euro.who.int/__data/assets/pdf_file/0008/355985/Health-Profile-Italy-Eng.pdf?ua=1
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Monica Crugnola, Fausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, Gabriele Gugliotta, and Fabio Stagno declare that they received speaker honorarium from Novartis, BMS, Incyte, Pfizer, Amgen. Massimiliano Bonifacio declares research funding from Novartis and speakers honorarium from BMS, Incyte, Pfizer. No conflict of interest has been declared from other authors. All procedure performed in this study were in accordance with ethical standards and with the Helsinki declaration. Informed consent was obtained from all individual participants included in this study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Crugnola, M., Castagnetti, F., Breccia, M. et al. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. Ann Hematol 98, 2329–2338 (2019). https://doi.org/10.1007/s00277-019-03767-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-019-03767-y